Prostaglandin (PG) D 2 is a PGH 2 metabolite deriving from the cyclooxygenase pathway and the major prostanoid released from activated human mast cells. The biological effects of PGD 2 are mediated by the G protein-coupled receptors (GPCRs) D-type prostanoid receptor (DP) and the chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). Eosinophils, important effector cells in allergy, express both receptors. Activation of CRTH2 has been shown to result in pro-inflammatory responses, while the role of DP in allergic inflammation is still unclear. In this study we show that PGH 2 selectively stimulates human peripheral blood eosinophils and basophils, but not neutrophils, and this effect is prevented by the CRTH2 receptor antagonist, Cay10471. In chemotaxis assays, eosinophils showed a pronounced migratory response towards PGH 2 , while eosinophil degranulation was inhibited by PGH 2 . Moreover, collagen-induced platelet aggregation was inhibited by PGH 2 in platelet-rich plasma, which was abrogated in the presence of the DP antagonist, BWA868c. HEK293 cells transfected with either human CRTH2 or DP responded with Ca 2+ flux, while untransfected HEK293 cells showed no response. These data indicate that PGH 2 causes activation of the PGD 2 receptors, CRTH2 and DP, even in the absence of functional PGD synthase. In further experiments, CRTH2 and DP receptors were stably co-expressed in HEK293 cells as a tool to explore receptor signalling and to investigate possible receptor heterodimerization. Data will be shown that demonstrate possible combinatorial effects of CRTH2 and DP to selective and non-selective agonists and antagonists in Ca 2+ signalling assays. 
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